BioVie (BIVI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$5.6M

Net income growth (year over year)

−61.80%

Net margin

—

Return on equity

−151.06%

EPS (trailing twelve months)

−$3.05

Book value per share

$1.36

P/E (trailing twelve months)

—

Price to book

1.03

Debt to assets

27.93%

Payout ratio

—

Dividend yield

—

Company profile

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

• How do I buy stock in BioVie (BIVI)?

  BIVI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.